Large scale phase 3 trials for an antibody drug is likely to begin in the United Kingdom, according to media sources. The drug is designed to protect people with a weakened immune system from COVID-19. The clinical trial will enroll 5,000 participants who are at increased risk of infection or who are more likely to have an inadequate response to vaccination and will include people from health care and care home settings. The aim of the trial is to evaluate the safety and effectiveness of AZD7442, a combination of two long-acting monoclonal antibodies – man-made proteins that act like natural human antibodies in the immune system. The drug is expected to give immediate protection to the recipient and protection could last for six months to a year.